1. The peptide backbone of tirzepatide is derived from which native incretin sequence, modified to confer balanced agonism at both incretin receptors?
A) The native glucose-dependent insulinotropic polypeptide (GIP) sequence, with amino acid substitutions that add balanced glucagon-like peptide-1 receptor (GLP-1R) activity
B) The native glucagon sequence, modified to remove all glucagon receptor activity
C) The native amylin sequence, extended to bind the glucagon-like peptide-1 receptor (GLP-1R)
D) The native insulin B-chain, engineered for incretin-receptor binding
E) The native leptin sequence, truncated to act at hypothalamic receptors
ANSWER: A
Rationale:
Tirzepatide is built on the native glucose-dependent insulinotropic polypeptide (GIP) sequence, into which amino acid substitutions are introduced that confer balanced agonist activity at both the GIP receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R).
Option B: Option B is incorrect because the backbone is not derived from glucagon; tirzepatide has no glucagon receptor activity, and a glucagon-derived backbone describes a different design strategy.
Option C: Option C is incorrect because amylin is the basis for analogs such as cagrilintide and pramlintide, not for tirzepatide.
Option D: Option D is incorrect because tirzepatide is an incretin-receptor agonist peptide, not an insulin-derived molecule.
Option E: Option E is incorrect because leptin is an adipokine unrelated to the incretin-receptor backbone of tirzepatide.
2. Tirzepatide and retatrutide are both single-peptide incretin-based agents. Which statement precisely distinguishes their receptor targets?
A) Tirzepatide is a triple agonist and retatrutide is a dual agonist
B) Tirzepatide is a dual agonist at the glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), whereas retatrutide adds glucagon receptor (GCGR) agonism to become a triple agonist
C) Both are selective glucagon-like peptide-1 receptor (GLP-1R) agonists with no other receptor activity
D) Tirzepatide targets the glucagon receptor (GCGR) and retatrutide targets the amylin receptor
E) Both agents are pure glucagon receptor (GCGR) agonists differing only in half-life
ANSWER: B
Rationale:
Tirzepatide is a dual agonist at the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), while retatrutide adds glucagon receptor (GCGR) agonism to the same GIPR/GLP-1R backbone, making it a triple agonist.
Option A: Option A is incorrect because it reverses the two agents, calling tirzepatide the triple agonist and retatrutide the dual agonist.
Option C: Option C is incorrect because neither agent is a selective GLP-1R agonist; both engage at least two receptors.
Option D: Option D is incorrect because tirzepatide does not target the GCGR and retatrutide does not target the amylin receptor; amylin agonism describes cagrilintide.
Option E: Option E is incorrect because neither agent is a pure GCGR agonist, and the distinction between them is the number of receptors targeted rather than half-life alone.
3. When glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism occurs alongside glucagon-like peptide-1 receptor (GLP-1R) activation, which effect is most specifically attributable to the GIPR component?
A) Slowing of gastric emptying as the dominant mechanism of satiety
B) Direct closure of pancreatic ATP-sensitive potassium channels independent of glucose
C) Enhanced glucagon suppression together with increased adipocyte insulin sensitivity and triglyceride uptake
D) Renal excretion of glucose through inhibition of sodium-glucose cotransporter-2 (SGLT-2)
E) Irreversible inhibition of dipeptidyl peptidase-4 (DPP-4)
ANSWER: C
Rationale:
In the context of concurrent GLP-1R activation, glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism adds incremental insulin secretion, enhances glucagon suppression, and increases adipocyte insulin sensitivity and triglyceride uptake, improving lipid handling in a way GLP-1R agonism alone does not achieve.
Option A: Option A is incorrect because slowing of gastric emptying is principally a GLP-1R-mediated action rather than the specific GIPR contribution.
Option B: Option B is incorrect because the incretin receptors act through glucose-dependent insulinotropic signaling, not by directly closing ATP-sensitive potassium channels in a glucose-independent manner, which is the sulfonylurea mechanism.
Option D: Option D is incorrect because renal glucose excretion via SGLT-2 inhibition is an unrelated drug class mechanism.
Option E: Option E is incorrect because inhibition of dipeptidyl peptidase-4 (DPP-4) describes the gliptin class, not GIPR agonism.
4. The hypothalamic arcuate nucleus (ARC) contains two antagonistic neuronal populations governing appetite. Which pairing correctly matches each population to its effect?
A) NPY/AgRP neurons are anorexigenic; POMC neurons are orexigenic
B) Both NPY/AgRP and POMC neurons are orexigenic
C) Both NPY/AgRP and POMC neurons are anorexigenic
D) NPY/AgRP neurons are orexigenic (appetite-promoting); POMC neurons are anorexigenic (appetite-suppressing)
In the arcuate nucleus (ARC), neurons co-expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) are orexigenic and promote food intake, whereas pro-opiomelanocortin (POMC) neurons are anorexigenic and suppress appetite; the balance between them sets the defended body weight.
Option A: Option A is incorrect because it reverses the two populations.
Option B: Option B is incorrect because the two populations are antagonistic, not both orexigenic.
Option C: Option C is incorrect because they are not both anorexigenic, again ignoring their opposing roles.
Option E: Option E is incorrect because it swaps the transmitters: POMC neurons release alpha-melanocyte-stimulating hormone, while NPY/AgRP neurons release neuropeptide Y and agouti-related peptide.
5. Agouti-related peptide (AgRP) and neuropeptide Y (NPY) are co-released by the same arcuate neurons but promote feeding through different molecular actions. What is the precise action of AgRP at the melanocortin 4 receptor (MC4R)?
A) It is a full agonist that activates the MC4R to suppress appetite
B) It is a competitive antagonist of neuropeptide Y receptors
C) It is a positive allosteric modulator that potentiates alpha-melanocyte-stimulating hormone signaling
D) It is an enzyme that degrades alpha-melanocyte-stimulating hormone in the synapse
E) It is an inverse agonist at the MC4R, blocking the anorexigenic alpha-melanocyte-stimulating hormone signal
ANSWER: E
Rationale:
Agouti-related peptide (AgRP) acts as an inverse agonist at the melanocortin 4 receptor (MC4R), blocking the anorexigenic signal carried by pro-opiomelanocortin-derived alpha-melanocyte-stimulating hormone and thereby promoting feeding; neuropeptide Y promotes feeding separately through its own receptors.
Option A: Option A is incorrect because AgRP opposes MC4R signaling as an inverse agonist rather than activating it as a full agonist to suppress appetite.
Option B: Option B is incorrect because AgRP acts at the MC4R, not as a competitive antagonist of neuropeptide Y receptors.
Option C: Option C is incorrect because AgRP blocks rather than potentiates alpha-melanocyte-stimulating hormone signaling, so it is not a positive allosteric modulator.
Option D: Option D is incorrect because AgRP is a signaling peptide acting at the MC4R, not an enzyme that degrades alpha-melanocyte-stimulating hormone.
6. The nucleus tractus solitarius (NTS) is a second central site where glucagon-like peptide-1 receptor (GLP-1R) agonism influences appetite. What is its specific role?
A) It is a brainstem nucleus that receives vagal afferent signals from gut mechanoreceptors and chemoreceptors and relays satiety information centrally
B) It is the hypothalamic nucleus that directly sets the body weight set point
C) It is the principal site of triglyceride synthesis in the central nervous system
D) It is the anterior pituitary region that releases alpha-melanocyte-stimulating hormone into the circulation
E) It is the pancreatic islet region where glucose-dependent insulin secretion occurs
ANSWER: A
Rationale:
The nucleus tractus solitarius (NTS) is a brainstem nucleus that receives vagal afferent input from gut mechanoreceptors and chemoreceptors and relays satiety information toward the hypothalamus; GLP-1R agonism here amplifies vagal satiety signaling, reducing meal size independently of the arcuate circuit.
Option B: Option B is incorrect because the body weight set point is governed by hypothalamic circuitry integrating leptin and insulin, not by the NTS.
Option C: Option C is incorrect because the NTS is a satiety-relay nucleus, not a site of central triglyceride synthesis.
Option D: Option D is incorrect because alpha-melanocyte-stimulating hormone is produced by hypothalamic pro-opiomelanocortin neurons acting locally on the melanocortin 4 receptor, not released into the circulation by the NTS.
Option E: Option E is incorrect because glucose-dependent insulin secretion occurs in pancreatic beta cells, not in this brainstem nucleus.
7. The "adipostat" model holds that the hypothalamus defends a body weight set point. As body weight falls during treatment, which hormonal change drives the compensatory orexigenic response?
A) A rise in leptin and insulin that increases anorexigenic POMC signaling
B) A rise in circulating amylin that suppresses appetite
C) A decline in leptin and insulin that increases orexigenic NPY/AgRP drive and decreases anorexigenic POMC signaling
D) A decline in glucagon that abolishes hepatic glucose production
E) A rise in alpha-melanocyte-stimulating hormone that increases food intake
ANSWER: C
Rationale:
As body weight and fat mass fall, leptin and insulin signaling decline; this loss of adiposity signaling increases orexigenic NPY/AgRP drive and decreases anorexigenic POMC signaling, producing the compensatory increase in appetite and reduced energy expenditure that defends the set point.
Option A: Option A is incorrect because leptin and insulin fall rather than rise with weight loss, and the net effect reduces, not increases, POMC signaling.
Option B: Option B is incorrect because the set-point defense is driven by falling adiposity signals, not by a rise in amylin suppressing appetite.
Option D: Option D is incorrect because the orexigenic rebound is governed by leptin and insulin changes acting on hypothalamic circuits, not by a decline in glucagon abolishing hepatic glucose production.
Option E: Option E is incorrect because alpha-melanocyte-stimulating hormone suppresses food intake; a rise in it would not drive an orexigenic response.
8. Glucagon receptor (GCGR) agonism in retatrutide carries a theoretical concern, which is counterbalanced within the same molecule. Which statement correctly pairs the concern with its counterbalance?
A) The concern is hypoglycemia, counterbalanced by the GCGR raising hepatic glucose output
B) The concern is worsening glycemia from glucagon-driven hepatic glucose output, counterbalanced by dominant GLP-1R-mediated insulin secretion and suppression of endogenous glucagon
C) The concern is excessive weight gain, counterbalanced by the appetite-stimulating effect of GLP-1R agonism
D) The concern is bradycardia, counterbalanced by GIPR-mediated heart rate increases
E) The concern is fluid retention, counterbalanced by GCGR-mediated diuresis
ANSWER: B
Rationale:
Because glucagon is a counter-regulatory hormone that raises hepatic glucose output, adding glucagon receptor (GCGR) agonism raises a theoretical concern of worsening glycemia; in retatrutide this is counterbalanced by the dominant GLP-1R-mediated, glucose-dependent insulin secretion and by GLP-1R-driven suppression of endogenous glucagon.
Option A: Option A is incorrect because the concern is hyperglycemia rather than hypoglycemia, and a counterbalance cannot be the very mechanism that causes the concern.
Option C: Option C is incorrect because the agent produces weight loss through added energy expenditure, and GLP-1R agonism suppresses rather than stimulates appetite.
Option D: Option D is incorrect because the relevant concern is glycemic, not bradycardia, and GIPR agonism is not invoked to raise heart rate as a counterbalance.
Option E: Option E is incorrect because the principal theoretical concern with GCGR agonism is glycemic, not fluid retention offset by diuresis.
9. Cagrilintide and pramlintide are both amylin-based agents. Which statement precisely distinguishes cagrilintide from the native peptide pramlintide?
A) Cagrilintide is a glucagon-like peptide-1 receptor (GLP-1R) agonist, whereas pramlintide is an amylin analog
B) Cagrilintide must be dosed three times daily, whereas pramlintide is a once-weekly agent
C) Cagrilintide blocks amylin receptors, whereas pramlintide activates them
D) Cagrilintide is engineered with a fatty acid chain for albumin binding, extending its half-life to roughly one week for once-weekly dosing, whereas pramlintide requires thrice-daily injection
E) Cagrilintide acts only on pancreatic beta cells, whereas pramlintide acts only in the liver
ANSWER: D
Rationale:
Cagrilintide is a long-acting amylin analog engineered with a fatty acid chain that promotes albumin binding, extending its half-life to approximately one week and enabling once-weekly subcutaneous dosing, in contrast to the native peptide pramlintide, which requires thrice-daily injection.
Option A: Option A is incorrect because both agents act on the amylin pathway; cagrilintide is not a GLP-1R agonist.
Option B: Option B is incorrect because it reverses the dosing schedules, assigning thrice-daily dosing to cagrilintide and once-weekly to pramlintide.
Option C: Option C is incorrect because cagrilintide activates rather than blocks amylin receptors, as does pramlintide.
Option E: Option E is incorrect because amylin agents act centrally at brainstem amylin receptors to reduce food intake, not by a beta-cell-only versus liver-only division.
10. Orforglipron and oral semaglutide are both taken by mouth, yet they differ fundamentally in chemical class and formulation. Which statement is correct?
A) Both are peptides requiring sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) coformulation
B) Both are small molecules absorbed without any permeation enhancer
C) Orforglipron is a peptide and oral semaglutide is a small molecule
D) Orforglipron requires strict fasting administration with a permeation enhancer, whereas oral semaglutide does not
E) Orforglipron is a non-peptide small molecule absorbed conventionally, whereas oral semaglutide is a peptide that requires the permeation enhancer sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) and fasting administration
ANSWER: E
Rationale:
Orforglipron is a non-peptide small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist whose oral bioavailability arises from conventional small-molecule absorption, so it does not need the permeation enhancer sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) or the strict fasting administration required by oral semaglutide, which is a peptide.
Option A: Option A is incorrect because orforglipron is not a peptide and does not require SNAC coformulation.
Option B: Option B is incorrect because oral semaglutide does require a permeation enhancer, so it is not true that both are absorbed without one.
Option C: Option C is incorrect because it reverses the chemical classes, calling orforglipron a peptide and semaglutide a small molecule.
Option D: Option D is incorrect because the fasting-plus-enhancer requirement belongs to oral semaglutide, not to orforglipron.
11. Tirzepatide's pharmacokinetic profile permits once-weekly subcutaneous dosing. Which combination of half-life and structural basis is correct?
A) A half-life of approximately five days, conferred by a fatty diacid moiety that promotes albumin binding
B) A half-life of approximately two hours, conferred by rapid renal clearance
C) A half-life of approximately thirty days, conferred by covalent binding to red blood cells
D) A half-life of approximately twelve hours, conferred by enterohepatic recirculation
E) A half-life of approximately five minutes, conferred by rapid dipeptidyl peptidase-4 (DPP-4) cleavage
ANSWER: A
Rationale:
Tirzepatide has a half-life of approximately five days, conferred by a fatty diacid moiety attached through a linker that promotes reversible binding to circulating albumin, slowing clearance and supporting once-weekly subcutaneous dosing.
Option B: Option B is incorrect because a two-hour half-life from rapid renal clearance would be incompatible with once-weekly dosing.
Option C: Option C is incorrect because tirzepatide does not covalently bind red blood cells and does not have a thirty-day half-life.
Option D: Option D is incorrect because the prolonged half-life derives from albumin binding rather than enterohepatic recirculation, and twelve hours would not support weekly dosing.
Option E: Option E is incorrect because the peptide is engineered to resist rapid degradation; a five-minute half-life describes native incretins subject to rapid dipeptidyl peptidase-4 (DPP-4) cleavage, not tirzepatide.
12. Which statement correctly describes the approved tirzepatide dosing schedule and maximum dose?
A) Initiated at 15 mg weekly and titrated downward by 2.5 mg every four weeks to the lowest effective dose
B) Initiated at 5 mg weekly with no maximum dose specified
C) Initiated at 2.5 mg subcutaneously once weekly and increased by 2.5 mg no more often than every four weeks, with a maximum dose of 15 mg weekly
D) Initiated at 2.5 mg daily and increased weekly to a maximum of 50 mg daily
E) Given as a single one-time dose of 15 mg with no titration
ANSWER: C
Rationale:
Tirzepatide is initiated at 2.5 mg subcutaneously once weekly and increased by 2.5 mg increments no more often than every four weeks toward the lowest effective dose, with approved doses up to a maximum of 15 mg weekly.
Option A: Option A is incorrect because therapy starts low and is titrated upward, not started at the maximum and reduced.
Option B: Option B is incorrect because a maximum dose of 15 mg weekly is specified.
Option D: Option D is incorrect because tirzepatide is dosed once weekly, not daily, and the maximum is 15 mg weekly rather than 50 mg daily.
Option E: Option E is incorrect because tirzepatide requires gradual titration rather than a single one-time dose.
13. Which statement correctly summarizes the contraindications and cautions for tirzepatide, which it shares with the glucagon-like peptide-1 receptor (GLP-1R) agonist class?
A) It is first-line monotherapy for type 1 diabetes mellitus (T1DM) and has no thyroid-related contraindication
B) It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), should not be used as sole glucose-lowering therapy in type 1 diabetes mellitus (T1DM), and is used with caution in patients with prior pancreatitis
C) It is contraindicated only in patients with hypertension and is otherwise unrestricted
D) It has no contraindications and may be combined freely with any other agent
E) It is contraindicated in all patients over age 65 regardless of comorbidity
ANSWER: B
Rationale:
Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), should not be used as sole glucose-lowering therapy in type 1 diabetes mellitus (T1DM), and is used with caution in patients with a history of pancreatitis.
Option A: Option A is incorrect because tirzepatide is not first-line monotherapy for T1DM and does carry the MTC/MEN2 thyroid contraindication.
Option C: Option C is incorrect because hypertension is not the defining contraindication; the MTC/MEN2 history is.
Option D: Option D is incorrect because the drug has defined contraindications and should not be combined with another GLP-1R agonist or pramlintide.
Option E: Option E is incorrect because there is no blanket age-based contraindication at 65; eligibility depends on comorbidity and the specific contraindications listed.
14. A patient with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin needs maximal glycated hemoglobin (HbA1c) reduction. Based on head-to-head trial evidence directly comparing the two incretin agents, which expectation is best supported?
A) Semaglutide 1 mg weekly produces substantially greater HbA1c reduction than tirzepatide at all doses
B) The two agents produce identical HbA1c reductions, so the choice is arbitrary
C) Tirzepatide worsens HbA1c relative to semaglutide
D) Tirzepatide at 5, 10, and 15 mg weekly produces greater HbA1c reduction than semaglutide 1 mg weekly
E) Neither agent meaningfully lowers HbA1c in patients on metformin
ANSWER: D
Rationale:
In a head-to-head comparison in patients with T2DM inadequately controlled on metformin, tirzepatide at 5, 10, and 15 mg weekly produced greater glycated hemoglobin (HbA1c) reductions than semaglutide 1 mg weekly, supporting tirzepatide when maximal glycemic lowering is the goal.
Option A: Option A is incorrect because it reverses the finding; tirzepatide, not semaglutide, produced the greater reduction.
Option B: Option B is incorrect because the reductions were not identical; tirzepatide was superior on this endpoint.
Option C: Option C is incorrect because tirzepatide improves rather than worsens HbA1c relative to semaglutide.
Option E: Option E is incorrect because both agents meaningfully lower HbA1c, and the comparison concerns the magnitude of benefit rather than absence of effect.
15. In obesity-related heart failure with preserved ejection fraction (HFpEF), how do the demonstrated outcomes of tirzepatide and semaglutide differ in clinical effect?
A) Tirzepatide showed only symptom improvement without any reduction in the combined cardiovascular event endpoint, whereas semaglutide reduced that endpoint
B) Both agents reduced the combined cardiovascular death or worsening heart failure event endpoint to the same degree
C) Tirzepatide reduced the composite of cardiovascular death or worsening heart failure events, whereas semaglutide improved symptom and functional measures without a significant reduction in that combined event endpoint
D) Neither agent produced any symptomatic or event benefit in HFpEF
E) Semaglutide reduced the combined event endpoint while tirzepatide worsened heart failure outcomes
ANSWER: C
Rationale:
In obesity-related HFpEF, tirzepatide demonstrated a significant reduction in the composite of cardiovascular death or worsening heart failure events, whereas semaglutide improved symptom burden and functional measures, such as a validated heart failure symptom score and walking distance, without a significant reduction in that combined event endpoint.
Option A: Option A is incorrect because it reverses the findings, denying tirzepatide its event reduction.
Option B: Option B is incorrect because the two agents did not reduce the combined event endpoint to the same degree; only tirzepatide significantly reduced that composite.
Option D: Option D is incorrect because both agents produced benefit, differing in whether the combined event endpoint was significantly reduced.
Option E: Option E is incorrect because tirzepatide improved, rather than worsened, heart failure outcomes.
16. For a patient with type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatohepatitis (MASH), how does tirzepatide compare with pioglitazone as a pharmacological option with hepatic benefit?
A) Pioglitazone, a glucagon-like peptide-1 receptor (GLP-1R) agonist, produces weight loss whereas tirzepatide causes weight gain
B) Both agents share the same mechanism and adverse-effect profile
C) Tirzepatide is a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, and pioglitazone is an incretin agonist
D) Tirzepatide promotes fluid retention and bone loss, whereas pioglitazone produces substantial weight loss
E) Tirzepatide offers glycemic control, weight reduction, and direct hepatic benefit, whereas pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with histological efficacy in MASH, promotes weight gain, fluid retention, and bone loss
ANSWER: E
Rationale:
For a patient with T2DM and MASH, tirzepatide combines glycemic control, substantial weight reduction, and direct hepatic benefit, whereas pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with demonstrated histological efficacy in MASH, promotes weight gain, fluid retention, and bone loss.
Option A: Option A is incorrect because pioglitazone is a PPAR-gamma agonist rather than a GLP-1R agonist, and it promotes weight gain while tirzepatide produces weight loss.
Option B: Option B is incorrect because the two agents have different mechanisms and very different adverse-effect profiles.
Option C: Option C is incorrect because it reverses the mechanisms, calling tirzepatide a PPAR-gamma agonist and pioglitazone an incretin agonist.
Option D: Option D is incorrect because fluid retention and bone loss are associated with pioglitazone, not tirzepatide, and pioglitazone does not produce substantial weight loss.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.